Popular weight-loss drugs may play surprising role in cancer outcomes

As GLP-1 medications continue reshaping the treatment of obesity and diabetes, researchers are also investigating whether the drugs could influence cancer risk and outcomes.

The American Association for Cancer Research's 2026 Cancer Progress Report, released earlier this month, noted that obesity is a major risk factor for many cancers.

As glucagon-like peptide-1 medications – including semaglutides like Ozempic and Wegovy, and tirzepatides like Mounjaro and Zepbound – are known to...